Page last updated: 2024-12-08

inositol 2,4,6-triphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID195079
CHEMBL ID3349692
CHEMBL ID103242
CHEBI ID46647
SCHEMBL ID4340928
SCHEMBL ID3496824
MeSH IDM0218413

Synonyms (29)

Synonym
114418-88-1
ins(1,3,5)p3
inositol-(1,3,5)-triphosphate
myo-inositol 1,3,5-tris(dihydrogen phosphate)
CHEBI:46647 ,
myo-inositol 1,3,5-trisphosphate
phosphoric acid mono-(2,4,6-trihydroxy-3,5-bis-phosphonooxy-cyclohexyl) ester
chembl3349692 ,
chembl103242
ins (1,3,5)p3
bdbm50132165
ins(2,4,6)p3
SCHEMBL4340928
(2,4,6-trihydroxy-3,5-diphosphonooxycyclohexyl) dihydrogen phosphate
myo-ins(2,4,6)p3
myo-inositol 2,4,6-trisphosphate
inositol 2,4,6-triphosphate
SCHEMBL3496824
RURWIJNHQMXJDV-GBKPYZKPSA-N
d-myo-inositol-1,3,5-tris(hydrogen phosphate)
d-myo-inositol-1,3,5-triphosphate
d-myo-inositol-1,3,5-trisphosphate
DTXSID00921367
2,4,6-trihydroxycyclohexane-1,3,5-triyl tris[dihydrogen (phosphate)]
Q27120669
(1r,2s,3r,4r,5s,6s)-2,4,6-trihydroxycyclohexane-1,3,5-triyl tris[dihydrogen (phosphate)]
FGV ,
PD053287
PD049295

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Phytate is an antinutritional factor that influences the bioavailability of essential minerals by forming complexes with them and converting them into insoluble salts."( β-propeller phytase hydrolyzes insoluble Ca(2+)-phytate salts and completely abrogates the ability of phytate to chelate metal ions.
Auh, JH; Choi, WC; Jung, WJ; Jung, YS; Kim, H; Kim, JW; Kim, KK; Kim, OH; Kim, YO; Lee, H; Lee, SJ; Oh, BC; Oh, TK; Shim, JH, 2010
)
0.36
"Phytate is an antinutritional factor that impacts the bioavailability of essential minerals such as Ca(2+), Mg(2+), Mn(2+), Zn(2+), and Fe(2+) by forming insoluble mineral-phytate salts."( Molecular and biochemical characteristics of β-propeller phytase from marine Pseudomonas sp. BS10-3 and its potential application for animal feed additives.
Auh, JH; Chun, KH; Kang, JK; Kim, YO; Ko, TK; Lee, CS; Lee, IK; Nam, SJ; Oh, BC; Park, S, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Inositol-trisphosphate 3-kinase ARattus norvegicus (Norway rat)IC50 (µMol)90.00002.60004.45006.3000AID92922
Sphingomyelin phosphodiesteraseHomo sapiens (human)IC50 (µMol)26.70005.00005.30005.6000AID1357899
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
symbiont entry into host cellSphingomyelin phosphodiesteraseHomo sapiens (human)
symbiont entry into host cellSphingomyelin phosphodiesteraseHomo sapiens (human)
plasma membrane repairSphingomyelin phosphodiesteraseHomo sapiens (human)
sphingomyelin metabolic processSphingomyelin phosphodiesteraseHomo sapiens (human)
sphingomyelin catabolic processSphingomyelin phosphodiesteraseHomo sapiens (human)
signal transductionSphingomyelin phosphodiesteraseHomo sapiens (human)
nervous system developmentSphingomyelin phosphodiesteraseHomo sapiens (human)
cholesterol metabolic processSphingomyelin phosphodiesteraseHomo sapiens (human)
response to xenobiotic stimulusSphingomyelin phosphodiesteraseHomo sapiens (human)
response to virusSphingomyelin phosphodiesteraseHomo sapiens (human)
response to ionizing radiationSphingomyelin phosphodiesteraseHomo sapiens (human)
termination of signal transductionSphingomyelin phosphodiesteraseHomo sapiens (human)
response to type I interferonSphingomyelin phosphodiesteraseHomo sapiens (human)
response to tumor necrosis factorSphingomyelin phosphodiesteraseHomo sapiens (human)
cellular response to UVSphingomyelin phosphodiesteraseHomo sapiens (human)
positive regulation of protein dephosphorylationSphingomyelin phosphodiesteraseHomo sapiens (human)
wound healingSphingomyelin phosphodiesteraseHomo sapiens (human)
response to cocaineSphingomyelin phosphodiesteraseHomo sapiens (human)
positive regulation of apoptotic processSphingomyelin phosphodiesteraseHomo sapiens (human)
negative regulation of MAP kinase activitySphingomyelin phosphodiesteraseHomo sapiens (human)
positive regulation of endocytosisSphingomyelin phosphodiesteraseHomo sapiens (human)
glycosphingolipid catabolic processSphingomyelin phosphodiesteraseHomo sapiens (human)
ceramide biosynthetic processSphingomyelin phosphodiesteraseHomo sapiens (human)
positive regulation of viral entry into host cellSphingomyelin phosphodiesteraseHomo sapiens (human)
symbiont entry into host cellSphingomyelin phosphodiesteraseHomo sapiens (human)
response to interleukin-1Sphingomyelin phosphodiesteraseHomo sapiens (human)
cellular response to calcium ionSphingomyelin phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
sphingomyelin phosphodiesterase activitySphingomyelin phosphodiesteraseHomo sapiens (human)
protein bindingSphingomyelin phosphodiesteraseHomo sapiens (human)
zinc ion bindingSphingomyelin phosphodiesteraseHomo sapiens (human)
hydrolase activity, acting on glycosyl bondsSphingomyelin phosphodiesteraseHomo sapiens (human)
phosphatidylcholine phospholipase C activitySphingomyelin phosphodiesteraseHomo sapiens (human)
acid sphingomyelin phosphodiesterase activitySphingomyelin phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
extracellular spaceSphingomyelin phosphodiesteraseHomo sapiens (human)
lysosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
extracellular spaceSphingomyelin phosphodiesteraseHomo sapiens (human)
lysosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
endosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
lipid dropletSphingomyelin phosphodiesteraseHomo sapiens (human)
plasma membraneSphingomyelin phosphodiesteraseHomo sapiens (human)
endolysosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
lamellar bodySphingomyelin phosphodiesteraseHomo sapiens (human)
lysosomal lumenSphingomyelin phosphodiesteraseHomo sapiens (human)
extracellular exosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1357899Inhibition of acid sphingomyelinase in human HuH7 cell lysate using NBD-sphingomyelin as substrate after 30 mins by TLC based fluorescence assay2018European journal of medicinal chemistry, May-10, Volume: 151Discovery of N-hydroxy-3-alkoxybenzamides as direct acid sphingomyelinase inhibitors using a ligand-based pharmacophore model.
AID92923Competitive inhibition of Inositol 1,4,5-trisphosphate 5-phosphatase1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Synthesis of selective non-Ca(2+)-mobilizing inhibitors of D-myo-inositol 1,4,5-trisphosphate 5-phosphatase.
AID92922Binding affinity against recombinant plasmid rat brain IP3K by overexpressing in Escherichia coli2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis of three enantiomeric pairs of scyllo-inositol phosphate and molecular interactions between all possible regioisomers of scyllo-inositol phosphate and inositol 1,4,5-trisphosphate 3-kinase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's2 (28.57)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.43 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]